RARE CANCERBile Duct CancerWHO 5th Edition Classification

Cholangiocarcinoma

Rare Malignancy (< 6 cases per 100,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

Cancer of the bile ducts, divided by anatomy into intrahepatic (within the liver), perihilar (at the junction of the main ducts, also called a Klatskin tumour) and distal. The distinction matters enormously: it determines the operation, the imaging pathway and, increasingly, the targeted therapy options, since actionable mutations cluster in intrahepatic disease.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Painless jaundice - image urgently and refer to a hepatobiliary centre
Who It Affects

Adults over 50; higher risk with primary sclerosing cholangitis, liver fluke infection, hepatolithiasis

Annual Incidence

Approximately 1-2 per 100,000 in Western countries, far higher in parts of Southeast Asia

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Yellowing of the skin and eyes, with dark urine and pale stools
Persistent itching
Right upper abdominal pain
Unexplained weight loss and loss of appetite
Fever with cholangitis if the duct becomes infected

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

FGFR2 fusions (intrahepatic)IDH1/IDH2BAP1HER2 amplification (distal)KRASMSI-H in a small subset

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Surgical resection - the only curative option, often with major liver resection

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Liver transplantation for selected perihilar tumours after neoadjuvant chemoradiation

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Gemcitabine-cisplatin plus durvalumab or pembrolizumab as first-line systemic therapy

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

FGFR inhibitors (pemigatinib, futibatinib) for FGFR2 fusion-positive disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Ivosidenib for IDH1-mutated disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

6

Biliary drainage by stent or drain for obstruction, and photodynamic therapy in selected cases

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Overall poor because most patients present unresectable, with five-year survival under 20%. Completely resected node-negative disease does considerably better. Molecularly targeted therapy has extended survival meaningfully in the FGFR2 and IDH1 subgroups, which makes comprehensive genomic profiling essential at diagnosis.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Next-generation FGFR inhibitors that overcome resistance mutations, HER2-directed therapy, and adjuvant immunotherapy trials are the main areas of development.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Cholangiocarcinoma

Browse All Oncologists

Dr. Ghassan K. Abou-Alfa

Medical Oncologist

25+ yrs exp

MSKCC

New York, USA

Hepatobiliary OncologyCholangiocarcinomaFGFR/IDH Inhibitors
Vetted DirectoryConsult Specialist

Dr. Joanne Ngeow

Medical Oncologist

15+ yrs exp

NCCS

Singapore, Singapore

Medical OncologyBiliary Tract CancersPrecision Oncology
Vetted DirectoryConsult Specialist

Prof. Juan Valle

Medical Oncologist

20+ yrs exp

The Christie

Manchester, United Kingdom

Medical OncologyCholangiocarcinomaABC Trials
Vetted DirectoryConsult Specialist

Dr. Amit Jain

HPB Surgeon

15+ yrs exp

ILBS

New Delhi, India

HPB SurgeryCholangiocarcinomaCurative Resections
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

rare

Cancer of Unknown Primary (CUP)

rare

Malignant Mesothelioma

rare

Retinoblastoma

rare

Ewing Sarcoma

Independent Tumor Board Review

Facing a Diagnosis of Cholangiocarcinoma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult